ASNC Issues Statement on How to Use HMDP in Cardiac Amyloidosis Imaging

ASNC Issues Statement on How to Use HMDP in Cardiac Amyloidosis Imaging

Shortages of pyrophosphate used to prepare 99mTc-PYP, the radiopharmaceutical most commonly used in the U.S. for noninvasive diagnosis of transthyretin (ATTR) cardiac amyloidosis, should not delay imaging in at-risk patients. Instead, ASNC is guiding imagers to use 99mtechnetium (99mTc)-hydroxymethylene diphosphonate (HMDP or HDP) to ensure patients continue receiving prompt evaluation of, and treatment for, cardiac amyloidosis.